tru4-1

Remdesivir is indicated for use in patients with mild-to-moderate disease.

There are multiple pathogenetic targets for treatment of SARS-CoV-2 infection.

SARS-CoV-2 penetrates its target cells via:

Classic types of vaccines are not applicable in the case of SARS-CoV-2.

Remdesivir and Molnupiravir belong to what class of therapeutic agents?